Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
U3 small nucleolar ribonucleoprotein protein IMP4 (IMP4) is a component of the 60–80S U3 small nucleolar ribonucleoprotein (U3 snoRNP) complex, which is essential for the early cleavage steps in pre-18S ribosomal RNA (rRNA) processing[2][3][5][6]. IMP4, along with IMP3 and MPP10, forms a stable heterotrimeric complex that binds to the U3 snoRNA within the nucleolus and is critical for the maturation of pre-rRNA during ribosome biogenesis[3]. IMP4 contains a characteristic Brix domain and a σ^70-like RNA-binding motif, supporting its interactions with RNA substrates and partner proteins. Although IMP4 is indispensable for ribosome biogenesis, there is currently no evidence to suggest it serves as a direct therapeutic target, biomarker, or drug-interacting protein[5][6]. Its role is crucial in supporting fundamental cellular processes rather than modulating disease-specific signaling or being a pharmacological target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U3 small nucleolar ribonucleoprotein protein IMP4 (IMP4).